Here’s a letter we received via email. Not sure if the links will work. Keep in mind that this is from the U.S. Around the corner for Canada, I hope.
Follow them on FaceBook, too.
Today is an extraordinary day for myeloma patients! Moments ago, the U.S. Food and Drug Administration (FDA) approved Pomalyst® (pomalidomide), an IMiD (in the same class as Revlimid®) as a treatment for patients with relapsed and refractory multiple myeloma.
For the past five years, the MMRF and our clinical research network, the MMRC, have proudly collaborated with Celgene to accelerate the early clinical trials that led to this historic approval. In bolstering the clinical development of this breakthrough treatment, we:
- Facilitated the clinical trials that provided the basis for Pomalyst’s accelerated approval
- Drove rapid patient enrollment to the trials, shortening the timeline to FDA approval by several months
- Continue to support the study of Pomalyst in additional clinical trials opened through the MMRC, including trials combining the drug with Kyprolis™ and Velcade®
The approval of Pomalyst is so critical because data show the drug works even in patients who no longer respond to other treatments like Velcade and Revlimid. Countless patients who have exhausted all other treatment options can now benefit from this new and much-needed therapy.
Check out the resources below for more information on Pomalyst:
- Read the MMRF press release on the FDA approval of Pomalyst
- Visit the MMRF website for detailed information about Pomalyst
- Register for a teleconference on February 28 on new therapies, including Pomalyst
On behalf of all those who will now benefit from this life-extending treatment, we extend our sincere gratitude to the FDA for recognizing the urgent need for expanded treatment options and to Celgene for its tireless commitment to patients with multiple myeloma and other cancers.
The Multiple Myeloma Research Foundation